Open innovations from AstraZeneca

AstraZeneca has launched the scientific platform "Open Innovations" to unite researchers from all over the world

AstraZeneca Biopharmaceutical Company announces the launch of a specialized portal designed to support innovative programs and improve interaction between the scientific community, pharmaceutical companies, non-profit organizations and the government.

The new online platform allows scientists to gain access to AstraZeneca's Open Innovation programs, which ensure that scientists fully comply with intellectual property rights and include:

• A "drug bank" containing the characteristics of small molecules and biologics ready for clinical testing; all molecules have demonstrated in clinical studies good tolerability and the expected effect on molecular targets in the human body. The bank includes both molecules whose development has been suspended, and molecules that are in active development. All molecules are provided for new clinical and translational studies.
• "Pharmacological Toolkit", which includes compounds with optimized pharmacological properties available for preclinical studies in order to study the biology of diseases.
• The program "Validation of new targets", in which scientists are given the opportunity to validate new hypothetical targets for new drugs, including the use of cutting-edge screening equipment.
• "Analysis of New Molecules" using chemoinformatics technologies, the purpose of which is to study the potential of innovative molecules in a particular therapeutic area.
• The program "Answers to scientific challenges", in which scientists will be able to offer their solutions to problems arising in the research projects of AstraZeneca.
• A "bank of Ideas", in which scientists will be able to make their own proposals for an innovative solution to a particular scientific problem. The researchers who came up with the best ideas will be awarded later.

Mene Pangalos, Executive Vice President of Innovative Drugs, AstraZeneca: "We strive to use different sources of scientific knowledge to develop innovative drugs to combat life-threatening diseases of our time. To do this, we decided to create a research environment accessible to all scientists, within which the scientific community, pharmaceutical companies and the government could actively interact with each other. I am very pleased that AstraZeneca has launched the Open Innovations platform, which allows us to work together with the world's leading researchers to develop drugs that change patients' lives for the better."

Portal "Eternal youth" http://vechnayamolodost.ru21.04.2014